| Admission fee | the goal | Stop Loss | potential |
|---|---|---|---|
|
€177.34 |
€188.4 |
€167 |
+6.24% |
The current trading zone is interesting and investors should keep a close eye on the stock and hope for a resumption of the underlying uptrend.
● The company presents an interesting fundamental picture from a short-term investment perspective.
● The company’s Refinitiv ESG Score, based on its ranking within its industry, is particularly well-received.
Strengths
● Analysts have a positive opinion on the stock, with the average consensus recommending the stock as Overweight or Buy.
Weaknesses
● Forecasts indicate that sales growth is expected to slow next fiscal year.
● The company’s current earnings per share (EPS) growth expectations over the next few years are a notable weakness.
• The Group has a fairly high level of debt relative to its EBITDA.
● Given the size of its balance sheet, the company appears to be highly valued.
● Over the past four months, revenue forecasts for the next few years have been revised downwards and a recovery in group activity is not yet expected.
● Over the past 12 months, analyst consensus has been revised downwards significantly.
● The price targets of various analysts that make up the consensus vary widely, reflecting different valuations and the difficulty of valuing a company.
© – 2024
The content published here is a general investment recommendation made by Surperformance, the publisher of MarketScreener.com, in accordance with regulations aimed at preventing market abuse. In particular, this recommendation is based on facts and expresses a good faith, complete and balanced opinion. This recommendation is based on internal or external data that is considered reliable as of the publication date. However, this information and the resulting recommendation may contain inaccuracies, errors or omissions, for which Surperformance assumes no responsibility. This recommendation does not constitute investment advice and may not be suitable for all investor profiles. The reader acknowledges and agrees that investing in financial products involves risks and assumes full responsibility for the same without recourse to Surperformance.Surperformance is committed to disclosing any conflicts of interest that may affect the objectivity of its recommendations.
